Scarica l'app Stockscreener
12.00
2.52%
-0.31
Dopo l'orario di chiusura:
12.00
Precedente Chiudi:
$12.31
Aprire:
$12.36
Volume 24 ore:
2.67M
Relative Volume:
1.56
Capitalizzazione di mercato:
$3.77B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-17.63
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
-3.54%
1M Prestazione:
+10.91%
6M Prestazione:
+61.73%
1 anno Prestazione:
+40.02%
Intervallo 1D:
$11.97
$12.37
Intervallo di 1 settimana:
$11.97
$12.68
Portata 52W:
$6.685
$12.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.00 | 3.87B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.44 | 56.08B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 45.68B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.67 | 43.64B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.88 | 30.66B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.14 | 20.67B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - MarketScreener
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Australia
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
How Amneal Pharmaceuticals Inc. stock compares to market leadersQuarterly Trade Report & Breakout Confirmation Alerts - Newser
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - MarketScreener
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - The Manila Times
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies - Quiver Quantitative
Amneal (NASDAQ: AMRX) gets FDA OK for cyclosporine 0.05% eye drug, Q1 2026 launch - Stock Titan
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25% - simplywall.st
Looking at the Narrative for Amneal as Analyst Targets Shift After Recent Milestones - Yahoo Finance UK
Is Amneal Pharmaceuticals Still an Opportunity After 61% Price Surge in 2025? - Yahoo Finance UK
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? - sharewise.com
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? - sharewise.com
Amneal gets FDA nod for Iohexol Injection - MSN
What insider trading reveals about Amneal Pharmaceuticals Inc. stockWeekly Trend Report & Smart Allocation Stock Tips - BỘ NỘI VỤ
Amneal Pharmaceuticals Outperforms Expectations And Raises Its Full-Year Outlook - Finimize
Assessing Amneal Pharmaceuticals (AMRX) Valuation Following FDA Approval for Generic Omnipaque Launch in 2026 - Sahm
Amneal Pharmaceuticals stock hits 52-week high at $12.12 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.12 - Investing.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Approval of First Generic Omnipaque - Sahm
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs - AOL.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - Finviz
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Ted Nark Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Is Amneal Pharmaceuticals Inc. stock trading near support levelsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
Amneal Pharmaceuticals Insider Sold Shares Worth $586,000, According to a Recent SEC Filing - MarketScreener
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Multi asset correlation models including Amneal Pharmaceuticals Inc.Trade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneWeekly Risk Report & AI Powered Market Entry Strategies - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Shareholder Nark Living trust U/A DTD 6/10/03 Files To Sell 50,000 Of Amneal Pharmaceuticals Inc [AMRX] - TradingView
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedVolume Spike & Fast Exit Strategy with Risk Control - newser.com
A Look at Amneal Pharmaceuticals’s Valuation Following FDA Approval and Upbeat Q3 Results - Sahm
Real time breakdown of Amneal Pharmaceuticals Inc. stock performancePortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayMarket Weekly Review & Weekly High Conviction Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutPortfolio Performance Summary & Weekly High Return Stock Opportunities - newser.com
Why The Narrative Around Amneal Is Shifting Amid Analyst Revisions and Recent FDA Approvals - Yahoo Finance
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):